Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fairly positive investor analysis for EGRX found at THIS LINKFor what it's worth, an excerpt:
Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 fourth quarter and full year financial results on Monday, March 2, 2020, before the market opens.
GLTA
Good Day Sprycel,
Coming over from the TYME board now. Hoping you're doing well. I'm pretty pleased with EGLX & THYME's basic partnership now. Thinking your brand has saved mine (and others).
Wishing for the best for ALL OF US.
Any insight you have is appreciated. Of course, this is true for any board member here.
You tell me yours, I'll tell you mine.
Damn, that's out of 6th grade:)
GLTUA
Good Day. Any hope here? With TYME board on this site.
Wishing all well.
Well after 2 years they got the FDA to back them up.
They finally did it after 2 years:
https://seekingalpha.com/news/3435579-fda-backs-exclusivity-eagle-pharmas-bendeka-late-2022
What is going on with this stock? Just keeps slipping, can’t hold ground.
Scott Tariff on Biologics acquisition
WIth a market cap of 880 million and cash on hand at 170 million, per last quarter earnings, Eagle has an EV of 710 million. Which I think looks pretty cheap.
Bendeka is now bringing in roughly 40 million in royalty revenue per quarter. However Treanda generics can launch in November of 2019.
So at the very least Eagle has another 8 quarters of 40 million royalty revenue coming there way. So at the very least, that leaves an EV of (710-320) of 390 million for the entire pipeline including Bendeka post 2019. Again this implies 0 dollars for Bendeka post generics which obviously will not happen.
So I personally think 390 million for the entire pipeline and Bendeka post 2019 generics if awfully cheap, however nothing comes easy for Eagle, most of their products require litigation against the novel drug's developer and Ryanodex expansion has been rough.
Eagle and the FDA are not seeing eye to eye on EHS expansion, Ecstasy and Meth trial recruitments are going slower than expected.
Sorry my post is a bit of rambling, I currently do not own any Eagle shares but will look to add when I have dry powder.
They are currently in litigation with Elly Lilly in regards to their pemetrexed generic so follow that case as it very likely will be the next newsworthy event for Eagle.
Have not been here in quite a while, not sure who’s the moderator or DD guru. Can you save me some up front time and give me the skinny on current position and pending developments, and should I dig deeper or just move on? Any help is greatly appreciated!!!!!
Dew how much of the 700 EV for Eagle would you ascribe to Bendeka?
Treanda generics hit the market in Nov 2019, so Eagle has approx 8 full quarters of 97% market share at roughly 40 million in Revenue per quarter.
I think its fair to say Bendeka is worth $400 million on the low side so that would leave $300 million to account Eagle's entire pipeline - Ryanodex, Pemetrexed, Falseodex.
If Lilly licenses Eagle's pemtrexed than Eagle is severely undervalued. I would model a partnership similar to that with TEVA, Pemetrexed generics won't hit until May 2022.
big news Only 40 mil market cap cash till 2020
Eagle Pharmaceuticals Announces Positive Results of Study Conducted to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure
http://investor.eagleus.com/press-release/eagle-pharmaceuticals-announces-positive-results-study-conducted-evaluate-neuroprotect
Eagle is going for a full on blockbuster drug with Ryanodex, just going to take some time.
Long term Eagle is undervalued here IMO, pemetrexed overhang currently keeping me out.
Suing the FDA for Bendeka's Orphan application was a huge mistake,
now FDA gets their revenge, they make the rules and change them
any way and time they want, it is better to get on with good side
of FDA, IMO.
Classic Scott Tarriff.... A typical salesman without situational awareness. Just empty fluff..
Remember when he sued the FDA for Bendeka's Orphan application?
He should feel lucky he stumbled on bendamustine.. All else is BS (Arsia, Ryanodex, Agniomax, etc, etc...)
EGRX receives CRL for Ryanodex in heatstroke: #msg-133316969.
Too hot to handle: Study shows Earth's killer heat worsens
https://www.yahoo.com/news/too-hot-handle-study-shows-150320127.html
Class action lawsuit update
Judge tosses Eagle Pharmaceuticals investors' case over rejected drug
Eagle Pharmaceuticals Inc has won the dismissal of a lawsuit accusing it of misleading investors about the likelihood of the company's gaining Food and Drug Administration approval to market a ready-to-use version of the blood thinner Angiomax.
U.S. District Judge Jose Linares in Newark, New Jersey, ruled the plaintiffs in the proposed class action lawsuit had not sufficiently alleged facts supporting their claim that Eagle's statements about the drug's characteristics were false.
Replacing a CFO is one of the biggest red flag's there is. No explanation from management makes it look even worse.
The president bought 200 shares? Are you kidding? Such a huge vote of confidence. lol
What about at the beginning CEO said more news on Monday
with earnings reports, but where is the news bedsides the
earnings report? My guess is what ever is the news, the deal
did not get done before Monday, hence the stock tanked from
95 to 86, some one knows what it is and coming up soon,
than we had the two days back up and holding today, feel
like HS approval any day, shouldn't take FDA that long to make
a decision since the data set is very small and Ryanodex
is already approved drug. we may see what ever the news
any day now, IMO.
Interesting comment from the Deutsche Bank conference about hopefully announcing "new licensing agreements over the course of the next month" for the biologics division.
33 mins into the webcast.
EGRX is acting strange(strong), is buyout from TEVA finally
happening or Ryanodex approval any day now leaked?
FDA Grants Priority Review for Eagle Pharmaceuticals’ Ryanodex NDA for the Treatment of Exertional Heat Stroke
http://investor.eagleus.com/press-release/fda-grants-priority-review-eagle-pharmaceuticals-ryanodex-nda-treatment-exertional-hea
EGRX Financial Update as of 12/31/16 from JP Morgan webcast
50 million - Cash
37 million - Accounts Receivable
25 million - Bendeka Milestone Payment anticipated in Q117
Tariff said they have bought 37 million worth of stock are are continuing to buy back their shares
also, said Eagle could benefit greatly from changes to corporate tax rates
Eli Lilly's Alimta escapes early generics—and a sales hit—with patent win over Teva
http://www.fiercepharma.com/pharma/eli-lilly-prevails-teva-s-alimta-patent-challenge
This was the first 2017 guidance for Bendeka/Treanda, so it wasn't actually lowered, but it was lower than investors expected. TEVA didn't give a reason for the low guidance, and no one on the hour-long CC last week asked about it.
My assumption is that the NHL/CLL arena is becoming more competitive with several newly approved drugs, which is reducing Bendeka/Treanda's market share.
But why did TEVA lower their sales guidance? Another drug on the market?
Low 2017 sales guidance for Bendeks/Treanda.
What was the reasoning for the drop?
EGRX -7% on TEVA’s 2017 guidance: #msg-127680719.
[OT]—MNTA's first NVS partnership deal (for generic Lovenox) was badly negotiated from MNTA's standpoint, and that gives me a somewhat negative opinion of Alan Crane. I don't feel strongly about it, however.
Dew are you aware that MNTA's former CEO Alan Crane is a Arsia Therapeutics co-founder?
Do you have an opinion on him?
Something to note here is that Eagle's largest shareholder, Proquest, who had been very active selling shares recently and who acquired their original stake of 4.8 million shares in the IPO, hasn't sold a share since the day after Eagle announced the acquisition.
Maybe they have sold and haven't had to file yet? I am not sure on all the legalities on 13D's
Proquest Claims to have over $900 million in management, this would make their share in Eagle approx. 1/3 of their entire portfolio. I would expect them to continue selling shares at returns of over 500%.
Maybe I am looking to far into this...
Instead of me trying to articulate why this doesn't make sense why don't we ask EGRX to articulate why it does and we can then collectively have a good laugh...(notice the market dropped 10% on the news of the agreement?)
All I'd like to say here is that many many "technology" companies tried to do what you suggest but realized that it ain't working.
msg was duplicated. Wouldn't let me delete this one.
"Who knows what Biogen and the other companies have in mind! They may have a great product that only needs the resolution of a viscosity problem but the core of their product is covered by some other IP. Does this even matter to EGRX? "
That's exactly what Eagles plans are.
Work with partners and license their technology to them to resolve the viscosity problem.
The partners will pay for all clinical trials.
Eagle would receive upfront, milestone and royalty payments.
Ryanodex is looking like its going to bring in a lot of profit once/if approved. I listened to the whole investment day recording and think that they greatly underestimated it themselves. $2300 a vial, likely $250M+ per year if approved for EHS. I'm liking where this company is going.
That's the problem with intellectual lightweights (Tarriff is just an example..). They pay more attention to what other people say and do rather than having knowledge and conviction themselves. Aware of their shortcomings, they easily get bedazzled by academic stars like Langer without understanding the fit to their business plan.
Who knows what Biogen and the other companies have in mind! They may have a great product that only needs the resolution of a viscosity problem but the core of their product is covered by some other IP. Does this even matter to EGRX?
What is the fit of ARSIA to EGRX? Can somebody articulate a scientifically sound rationale? Does EGRX have any scientists, patents, know-how that gets complemented by ARSIA? Does EGRX even understand what biologics and biosimilars are?
For all I know, Langer&Co found a bunch of bumpkins loaded with money (just by serendipity...) and they sold them a waaaay overvalued asset..
I guess Biogen and 11 other companies that Arsia has deals with do not believe its a bluff.
Biogen's deal is worth 100Mil
Dew, I fully understand your disappointment.
I voiced concerns about Tarriff in the past (ethics at Par, understanding technology, etc) and today he just proved me right. As somebody with low self-confidence would do, he was bedazzled by academic titles, ignored the fundamentals and ventured into something he (and his organization) doesn't understand and don't have the horsepower to compete in..Arsia seems more like an academic bluff rather than a real company.
To put it simply, creating solid IP around viscosity modification is next to impossible. Somebody will always find something better (or close enough..).
Pity...
I cashed out today (#msg-126485051), so I'm resigning as board moderator.
EGRX still has a lot of potential, of course, but the risk/reward tradeoff just became less favorable, IMO.
GLTA
I wasn't expecting this move (see bottom of #msg-126484009), but the company being acquired has some high-profile principals.
Eagle Pharmaceuticals Initiates Rolling Submission of NDA for Ryanodex in Exertional Heat Stroke
http://investor.eagleus.com/press-release/eagle-pharmaceuticals-initiates-rolling-submission-nda-ryanodex-exertional-heat-stroke
Eagle Pharmaceuticals Signs Definitive Agreement to Acquire Arsia Therapeutics Marking Entry into Biosimilar Market
http://investor.eagleus.com/press-release/eagle-pharmaceuticals-signs-definitive-agreement-acquire-arsia-therapeutics-marking-en
In regards to milestone, the answer is yes
Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results
http://investor.eagleus.com/press-release/eagle-pharmaceuticals-inc-reports-third-quarter-2016-results
-- Bendeka achieves market share of 88% --
-- CMS establishes unique J-Code for Bendeka --
-- Positive initial results of Ryanodex in MDMA animal study --
-- Q3 EPS increases to $0.77 per basic and $0.73 per diluted, Total Revenue $37.8 million --
The Bendeka "take-back" rights apply only when there is generic competition and no J-code, so this feature of the TEVA-EGRX collaboration no longer pertains.
The royalty step-up to 25% under the delayed J-code scenario (what we not have) hasn't been publicly disclosed, but EGRX may have disclosed it to the analyst who stated it is happening in Jan 2017.
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
592
|
Created
|
06/22/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |